GSK Reports Strong Q1 Earnings with Sales Growth and Guidance Reiteration
GSK reported strong Q1 results with sales rising 5% to GBP 7.6 billion, driven by specialty medicines and the Shingrix vaccine. The company reiterated full-year guidance and highlighted progress in its long-acting HIV franchise and pipeline developments. Key product launches and clinical milestones were also emphasized.
Tickers: $DHI $GSK $MRK $NVR $PHM
Topics: Acquisitions Dividend Earnings Hepatitis B HIV Treatment Pipeline Development Profit Sales Growth